Hence, modulation of the endocannabinoid system in recently diagnosed AD patients by daily management of low doses of cannabinoids could at minimum delay the progression of the disease, i.e. reducing inflammation, sustaining potential for neurogenesis, reducing hyperphosphorylation of Tau and delaying memory impairment. This evidence concerns the gene MAPT and memory impairment.